RBS2418 for Advanced Colorectal Cancer
This study is evaluating RBS2418, a drug designed to boost your body's immune response against cancer, in people with advanced, metastatic (spread to other parts of the body), and progressive colorectal cancer. RBS2418 works by protecting a natural substance in your body (cGAMP) that helps activate immune cells. Researchers want to see if RBS2418, compared to a placebo (an inactive substance), is safe, well-tolerated, and can lead to anti-tumor effects. You may be eligible if you are at least 18 years old and have colorectal cancer that has progressed after, or if you cannot receive, standard treatments. The main goals are to see how long people live without their cancer getting worse (progression-free survival) and how long they live overall (overall survival), both measured for up to two years.
- Study design
- This is an interventional study with a planned enrollment of 150 participants. Participants will receive either RBS2418 or a placebo.
- What's involved
- Participants will receive study treatment in 21-day cycles for up to two years, or until their disease progresses, they withdraw, or the study ends. Adverse events will be monitored throughout and after treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- Adverse events will be collected for up to 30 days after treatment, and serious adverse events for 90 days after treatment or 30 days after starting new anti-cancer therapy.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
At a glance
Conditions
Where it's being run
5 sites across 5 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Progression Free SurvivalFrom randomization until the first radiographic documentation of objective progression or death from any cause, assessed up to 2 years.
Time in months from randomization until the first radiographic documentation of objective progression, as assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, or death from any cause
- Overall SurvivalFrom randomization until death from any cause, assessed up to 2 years.
Time in months from the date of randomization to the date of death from any cause